Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label drug-drug interaction study of nipocalimab with etanercept or hydroxychloroquine in healthy participants
NL-OMON49934Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of nipocalimab, etanercept and hydroxychloroquine in autoimmune disease and Inflammatory Disorders (3 arms), sponsored by Janssen Pharmaceutical. Started Aug 2021; status: completed.
02
Drugs
nipocalimabetanercepthydroxychloroquine
03
Conditions
autoimmune diseaseInflammatory Disorders
Beyond the preview
Go deeper on NL-OMON49934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49934.